Blood test may detect precancerous changes in the ovary. Researchers report 92 percent sensitivity
Scientists have developed a test based on the Tu-Stroma molecule that could help detect changes preceding ovarian cancer earlier, a disease usually diagnosed only at an advanced stage.

National Cancer Institute · Unsplash License
- 0views
- 0likes and saves
- 0skips
In brief
- Researchers have developed a blood test that measures the Tu-Stroma molecule, which is linked to precancerous changes in the ovary.
- Ovarian cancer usually causes no symptoms and is often detected at an advanced stage.
- The study included more than 500 patients; the test detected 92% of changes preceding ovarian cancer.
- The result comes from research studies, and the test is not yet available in clinical practice.
A silent adversary and the problem of early detection
Ovarian cancer in most cases develops without symptoms, which is why it is most often diagnosed when the disease is already far advanced (Breakthrough in the fight against ovarian cancer. A blood test will detect precancerous changes – RMF24). For years, specialists have pointed out that the available detection methods are insufficient, especially for high-grade serous cancer, the most dangerous form of this tumor.
Lesions in the fallopian tube as a starting point
The researchers focused on STIC lesions. These are microscopic forms of cancer that develop not in the ovary itself but in the fallopian tube, and they can remain invisible in standard tests for a long time. During the analysis, a special type of RNA called Tu-Stroma was detected. Its elevated level in the blood may indicate the presence of early precancerous lesions.
Test results
The team developed a blood test measuring the concentration of Tu-Stroma. The study included more than 500 patients: healthy women, patients at various stages of ovarian cancer, and women with benign adnexal changes. According to the researchers' results, the test detected 92% of changes preceding ovarian cancer (Blood test detected 92 percent of changes preceding ovarian cancer. Better than the current marker – rynekzdrowia.pl).
What comes next
The result is promising, but these are still results from research studies. The test is not available in doctors' offices or healthcare facilities, and its usefulness in routine practice requires further research. Women with concerning symptoms, such as persistent abdominal pain, bloating, or feeling full quickly, should consult a gynecologist.
Sources
Discussion0
- No comments from this perspective yet. Be the first.
